HOTH News and Press, Hoth Therapeutics Inc. From 06/15/20

NEW YORK , June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters , Ph.D., Professor, Department of Chemi...

Hoth Therapeutics ( HOTH +4.8% ) announces that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAMBA Retinamides that Degrade MNKs for Treating Cancer". More news on: Hoth Therapeu...

NEW YORK , June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAM...

June 3, 2020 Palm Beach, FL – June 3, 2020 – Rapid development of a vaccine to prevent the global health crisis is a global imperative, and defining the stakes and potential hurdles is critical because regulatory and medical decisions are based on benefit/risk calcul...

NEW YORK , June 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as ...

NEW YORK , May 27, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182 shares of its common stock, at a price to the ...

Recon Technology (NASDAQ: RCON ) -38%  on ~$2.1M registered direct offering . More news on: Recon Technology, Ltd., Geron Corporation, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...

NEW YORK , May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters , Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COV...

Hoth Therapeutics (NASDAQ: HOTH ) has priced its public offering of 1,818,182 common shares at $2.75/share, for gross proceeds of ~$5M. More news on: Hoth Therapeutics, Inc., Healthcare stocks news, , Read more ...

NEW YORK , May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75...